Mera Pharmaceuticals Stock Performance
| MRPI Stock | USD 0.0001 0.00 0.00% |
The company secures a Beta (Market Risk) of 0.0, which conveys not very significant fluctuations relative to the market. the returns on MARKET and Mera Pharmaceuticals are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Mera Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong basic indicators, Mera Pharmaceuticals is not utilizing all of its potentials. The current stock price confusion, may contribute to short-horizon losses for the traders. ...more
Mera |
Mera Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 0.01 in Mera Pharmaceuticals on October 15, 2025 and sell it today you would earn a total of 0.00 from holding Mera Pharmaceuticals or generate 0.0% return on investment over 90 days. Mera Pharmaceuticals is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Mera, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Mera Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Mera Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Mera Pharmaceuticals, and traders can use it to determine the average amount a Mera Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| MRPI |
Based on monthly moving average Mera Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Mera Pharmaceuticals by adding Mera Pharmaceuticals to a well-diversified portfolio.
Mera Pharmaceuticals Fundamentals Growth
Mera Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Mera Pharmaceuticals, and Mera Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Mera Pink Sheet performance.
| Return On Asset | -1.74 | |||
| Current Valuation | 167.19 K | |||
| Shares Outstanding | 557.3 M | |||
| Price To Sales | 3.62 X | |||
| Revenue | 302.62 K | |||
| EBITDA | (192.75 K) | |||
| Cash And Equivalents | 4.32 K | |||
| Total Debt | 299.14 K | |||
| Cash Flow From Operations | (71.84 K) | |||
| Total Asset | 71 K | |||
| Retained Earnings | (8.89 M) | |||
| Current Asset | 54 K | |||
| Current Liabilities | 935 K |
About Mera Pharmaceuticals Performance
By evaluating Mera Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Mera Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Mera Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Mera Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Mera Pharmaceuticals, Inc. focuses on the development and commercialization of natural products from microalgae using its proprietary and large-scale photobioreactor technology. Mera Pharmaceuticals, Inc. was founded in 1983 and is based in Las Vegas, Nevada. Mera Pharma is traded on OTC Exchange in the United States.Things to note about Mera Pharmaceuticals performance evaluation
Checking the ongoing alerts about Mera Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Mera Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Mera Pharmaceuticals generated a negative expected return over the last 90 days | |
| Mera Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Mera Pharmaceuticals currently holds 299.14 K in liabilities. Mera Pharmaceuticals has a current ratio of 0.06, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Mera Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Mera Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Mera Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Mera to invest in growth at high rates of return. When we think about Mera Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 302.62 K. Net Loss for the year was (5.58 K) with profit before overhead, payroll, taxes, and interest of 286.36 K. | |
| Mera Pharmaceuticals currently holds about 4.32 K in cash with (71.84 K) of positive cash flow from operations. |
- Analyzing Mera Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Mera Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Mera Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Mera Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Mera Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Mera Pharmaceuticals' pink sheet. These opinions can provide insight into Mera Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Mera Pink Sheet analysis
When running Mera Pharmaceuticals' price analysis, check to measure Mera Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mera Pharmaceuticals is operating at the current time. Most of Mera Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Mera Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mera Pharmaceuticals' price. Additionally, you may evaluate how the addition of Mera Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |